MBX Biosciences reported first quarter 2026 financial results, with cash and investments of $440 million expected to fund operations into 2029. The clinical-stage biopharmaceutical company is developing precision peptide therapies for endocrine and metabolic disorders. The company's Phase 2 trial results for once-weekly canvuparatide, a hypoparathyroidism treatment, have been accepted for presentation at ENDO 2026 in June. A Phase 3 trial is on track to begin in Q3 2026 following a successful FDA meeting. MBX appointed Mark Soued as Chief Commercial Officer to add launch and commercialisation expertise. The company plans to host an Obesity Day on 11 May featuring blinded data from its ongoing MBX 4291 Phase 1 trial. First quarter net loss was $23.5 million, compared to $23.9 million in the same period last year.

MBX Biosciences announces appointment of Mark Soued as Chief Commercial Officer and Inducement Grant award. GlobeNewswire | MBX Biosciences, Inc. Today at 4:00am PDT CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) - MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Mark R. Soued, MBA, as Chief Commercial Officer (CCO). Mr. Soued brings more than two decades of commercial leadership across global biopharmaceutical organizations, with deep expertise in product launches, market access, and building high-performing commercial teams. "Mark is an exceptional commercial leader with a demonstrated ability to build and scale commercial organizations and bring products to market," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "His track record of delivering landmark product launches and generating significant revenue growth at organizations like Alnylam and Pfizer makes him uniquely positioned to lead MBX's commercialization efforts as we continue to advance our pipeline of clinically validated, proprietary Precision Endocrine Peptides(TM)." "I am excited to join MBX Biosciences at such a pivotal moment in the company's development," said Mr. Soued. "The team has built a differentiated pipeline and world-class team with the potential to meaningfully address unmet needs in endocrine and metabolic diseases. I look forward to helping shape and execute a commercial strategy that brings these therapies to the patients who need them most." Mark Soued is a seasoned commercial biopharma executive with extensive experience building and growing global commercial organizations overseeing multiple product launches, sales and marketing, market access, and lifecycle management. Most recently, Mr. Soued served as Senior Vice President, Head of US at Alnylam Pharmaceuticals, where he led the Company's US amyloidosis business, including the category-defining launch of AMVUTTRA(R) in ATTR cardiomyopathy. Prior to that, he served as Senior Vice President, Head of Global Commercial at Alnylam, where he built a global commercial organization spanning six functions and four inline products. Earlier in his career, Mr. Soued held a series of senior commercial leader roles at Pfizer, including Regional President for North America's Hospital Business Unit, Vice President and Global Rare Cardiology Franchise Head, and multiple international leadership positions across Asia Pacific and Northwestern Europe. He led the successful US launch of VYNDAQEL(R)/VYNDAMAX(R) and negotiated a multi-billion US government contract for PAXLOVID(R), among other milestones. Mr. Soued holds an MBA from Northwestern University's Kellogg School of Management and a B.S. in Finance from the University of Colorado. He is fluent in English and French. Inducement Grant In connection with the appointment of Mr. Soued as Chief Commercial Officer, on May 1, 2026, MBX granted Mr. Soued an inducement equity award, which was approved by the Company's board of directors in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement award consisted of non-qualified stock options to purchase an aggregate of 160,000 shares of the company's common stock with an exercise price of $29.78 per share, which is equal to the closing price of the company's common stock as reported by Nasdaq on May 1, 2026. The option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of April 29, 2026, and the remainder vesting in 36 equal monthly installments for the three years thereafter, subject to Mr. Soued's continued service. The award is subject to the terms and conditions of the company's 2026 Inducement Plan and the terms and conditions of the stock option agreement covering the grant. About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP(TM) platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences' expectations regarding Mr. Soued's ability to help advance commercialization, MBX Biosciences' expectations regarding the further advancement of its pipeline of programs in endocrine and metabolic disorders; and MBX Biosciences' plans for delivery of differentiated endocrine and metabolic compounds to underserved patients. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences' business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company's research and development activities; uncertainties relating to preclinical and clinical development activities; uncertainties relating to preclinical and clinical development activities; the risk that preliminary results may not be indicative of later results; MBX Biosciences' ability to attract, integrate and retain key personnel; as well as other risks described in "Risk Factors," in MBX Biosciences' Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. MBX uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.

MBX Biosciences to host in-person and virtual Obesity Day on May 11, 2026 to discuss expanding obesity portfolio. Rhea-AI Impact Rhea-AI Sentiment (Very Positive) Rhea-AI summary. MBX Biosciences (Nasdaq: MBX) will host an in-person and virtual Obesity Day on May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio and Precision Endocrine Peptide(TM)(PEP(TM) platform. Speakers include Richard DiMarchi, Ph.D., and Katherine H. Saunders, M.D., followed by a live Q&A. The live webcast is available in the Events section of the MBX Biosciences investor website and a replay will be archived for ~90 days. News market reaction - MBX. Key figures. Pro forma cash & investments: $459.1M 2025 net loss: $87.0M ATM capacity: $250,000,000 +5 more Market reality check. Price: $33.39 Vol: Volume 341,749 is below t... normal vol Peers on argus. MBX was up 1.02% while only one peer, FDMT, appeared in momentum scans, rising 7... Historical context. 5 past events · Latest: Mar 12 (Positive) Pattern 5 events Regulatory & risk context. Active S-3 Shelf · $250,000,000 Shelf Active Market pulse summary. This announcement schedules an Obesity Day to highlight MBX's expanding obesity portfolio and Precis... AI-generated analysis. Not financial advice. 04/23/2026 - 05:00 AM The event will feature Richard DiMarchi, Ph.D. (Distinguished Professor of Chemistry, Indiana University; Scientific Co-Founder, MBX Biosciences, Inc.) and Katherine H. Saunders, M.D. (Co-Founder, FlyteHealth; Clinical Assistant Professor of Medicine, Weill Cornell Medicine), who will join company management to discuss the evolving treatment landscape and remaining treatment gaps in obesity. MBX management will provide an overview of MBX's Precision Endocrine Peptide(TM)(PEP(TM) platform and its application to the development of long-acting peptide therapies for obesity, as well as an update on the Company's obesity product candidates. A live Q&A session will follow the formal presentations. The live webcast can be accessed in the Events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. A replay of the webcast will be archived on the Company's website for approximately 90 days. About Richard DiMarchi, Ph.D. Richard DiMarchi, Ph.D., is a Distinguished Professor of Chemistry at Indiana University and a globally recognized leader in peptide drug design, with prior senior leadership roles at Eli Lilly and Novo Nordisk. He is recognized for his contributions to the discovery and development of Humalog(R), rGlucagon(R), and Forteo(R), and his research has advanced the understanding of glucagon biology and the development of single-molecule multi-agonists for metabolic diseases, including the first GLP-1/GIP co-agonist and GLP-1/GIP/glucagon triple agonist. As Scientific Co-Founder of MBX Biosciences, he has helped pioneer the Company's PEP(TM) platform, including its pipeline of novel peptide-based drug candidates. He is a member of the National Academy of Medicine and the National Inventors Hall of Fame and is co-inventor on more than 100 U.S. patents with over 300 scientific publications with an h-index >85. About Katherine H. Saunders, M.D. Katherine H. Saunders, M.D., is a physician entrepreneur and internationally recognized expert in obesity medicine, focused on advancing effective, evidence-based care for patients with obesity and associated comorbidities. She is Co-Founder of FlyteHealth, a company dedicated to expanding access to cardio-kidney-metabolic treatment and serves on faculty at Weill Cornell Medicine. Dr. Saunders completed her medical training at Weill Cornell Medical College and NewYork-Presbyterian/Weill Cornell, where she was the first fellow in obesity medicine. She is board-certified in Internal Medicine and Obesity Medicine, has authored more than 50 peer-reviewed publications, and is a frequent speaker and media contributor on the evolving obesity treatment landscape. About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP(TM) platform, for the treatment of endocrine and metabolic disorders. The company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the company website at www.mbxbio.com and follow it on LinkedIn. Media Contact: George Shea We. Communications [email protected] (937) 232-4889 Investor Contact: Jim DeNike MBX Biosciences [email protected] Faq. When is MBX Biosciences' Obesity Day and how can I attend the May 11, 2026 event? The event is on May 11, 2026 at 10:30 a.m. ET; attendance is available in person or virtually. According to MBX Biosciences, registration details and the live webcast link are provided on the company's Events page for investors. Who are the featured speakers at MBX Biosciences Obesity Day (MBX) on May 11, 2026? Featured speakers include Richard DiMarchi, Ph.D., and Katherine H. Saunders, M.D., alongside MBX management. According to MBX Biosciences, they will discuss the evolving obesity treatment landscape and remaining treatment gaps. What topics will MBX Biosciences cover during the May 11, 2026 Obesity Day webcast? MBX will overview its PEP(TM) platform, long-acting peptide therapies for obesity, and obesity product candidate updates. According to MBX Biosciences, presentations will cover scientific rationale and program status, followed by a live Q&A session. Where can investors find the MBX Biosciences (MBX) Obesity Day webcast and replay after May 11, 2026? The live webcast is accessible in the Events section of the MBX Biosciences investor website; a replay will be archived for about 90 days. According to MBX Biosciences, the replay link will remain available on the company site. Will MBX Biosciences (MBX) provide time for audience questions during the May 11, 2026 presentation? Yes. A live Q&A session will follow the formal presentations to allow audience questions. According to MBX Biosciences, management and invited speakers will participate in the live question-and-answer period.